Pre-market Hot Trades in US Stocks

BrenX, up 16.55% in pre-market trading, has no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Biodexa Pharmaceuticals, down 14.41% in pre-market trading, has no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Top Gainers in Pre-market US Stocks

Polestar Automotive UK PLC - CW 27, up 92.49% in pre-market trading, has no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

YY, up 78.26% in pre-market trading. Based on recent key news:

1. On August 25, YY Group announced the cancellation of a $5.94 million second round of financing and the cancellation of all outstanding warrants. This move effectively reduces the company's potential equity dilution, enhances investor confidence, and drives the stock price significantly higher.

2. On August 25, YY Group's financial condition and liquidity were affected by industry competition, government policies, and regulations. The company discussed these risk factors in detail in its latest 20-F annual report, and investors are optimistic about the company's future financial performance.

3. On August 25, YY Group's Chief Financial Officer Jason Zhi Yong Phua communicated with investors, emphasizing the company's response strategies under market and regulatory conditions, further boosting market confidence. The market reacted positively to the company's dilution reduction.

CID Holdco, up 45.36% in pre-market trading. Based on recent key news:

1. On August 25, Expion's stock price rose about 80% due to its major strategic expansion in the upstream energy sector. This move is viewed positively by the market, driving the stock price significantly higher.

2. On August 25, Valion Bio Inc announced that the Ukrainian Ministry of Health accepted its regulatory documents for Entolimod for formal review. After rising over 35% on Monday, the stock fell 14.8% in pre-market trading. This news has sparked market interest in its future growth potential.

3. On August 25, Aclaris Therapeutics Inc's stock fell 12.7% in pre-market trading after releasing optimistic quarterly results. Despite good performance, the market remains cautious about its future profitability. The energy sector expansion has drawn market attention